The official mechanics matter here. FDA says the openFDA drug enforcement endpoint is built from the Recall Enterprise System, is updated weekly, and includes recalls once they are classified; the enforcement-report field definition says report_date is the weekly enforcement report date. The main Enforcement Report documentation likewise describes the report as a weekly publication and explains that classified recalls are posted there after FDA completes its hazard assessment. So this market resolves on nine weekly report dates in the June 10, 2026 through August 5, 2026 window, not on recall initiation dates. (open.fda.gov)

As of the official openFDA API snapshot visible on June 10, 2026, the drug enforcement endpoint had last_updated = 2026-06-03 and total = 17,683 records; the overview page says the dataset covers 2004-present and is updated weekly. That gives a rough all-classes baseline of about 17,683 records over a little more than 22 years, or roughly 800 drug-enforcement rows per year across Class I/II/III combined. (api.fda.gov)

The hard part is the Class I share. FDA defines Class I as the highest-hazard tier, meaning reasonable probability of serious adverse health consequences or death, so it should be only a minority of all drug enforcement rows. I could not extract a full official historical Class I time series in this environment, so I supplemented the top-down official baseline with recent row-level examples from a non-official mirror of FDA recall records only to judge clustering, not to define resolution. Those examples show that Class I drug recalls are lumpy: one underlying event can generate multiple recall numbers on the same report date, e.g. ICU/Otsuka had 2 Class I rows reported on November 26, 2025; B. Braun had at least 2 Class I rows reported on September 10, 2025; Harvard/Rugby had 2 Class I rows reported on November 29, 2023; and Today The World had 3 Class I rows reported on February 28, 2024. That pattern argues against a simple low-variance Poisson model. (fda.gov)

My synthesis is: start from the all-classes baseline, assume Class I drug rows are only a few percent of all drug enforcement rows, then scale to a 57-day window and add overdispersion for clustering. A few-percent Class I share implies a window mean around 3 to 6 rows; clustering examples push me away from the low end of variance but not toward an extreme mean. I therefore use a negative-binomial forecast with mean 4.3 and moderate overdispersion (k = 2.4). That makes 4 the single best point estimate, puts most mass from about 1 to 8, leaves a real but not dominant chance of 0, and keeps a noticeable tail for a multi-row summer cluster. (api.fda.gov)

I centered the forecast on the number of row-level Class I drug enforcement records, not on company announcements. That distinction matters because the openFDA drug enforcement endpoint is the resolution source, it uses report_date as the date FDA issued the enforcement report, and the endpoint is updated weekly rather than continuously. The openFDA overview page also recently showed its covered period ending at 2026-05-27, which is evidence of a real publication lag between an enforcement report date and when that date is visible in openFDA. (open.fda.gov)

For a base rate, I used FDA’s own recent annual recall-classification summaries. In 2023, CDER’s Office of Compliance said it classified 264 drug recall events, including 28 Class I events, 172 Class II, and 64 Class III. In 2025, it reported 321 drug recall events, and the classification figure shows 29 Class I, 256 Class II, and 36 Class III. So the recent annual pace for Class I drug recall events has been very stable at roughly 28-29 per year. (fda.gov)

The target window, June 10, 2026 through August 5, 2026 inclusive, is 57 days, or about 15.6% of a year. Applying that fraction to a 28-29 annual event pace gives a naive expectation of about 4.4-4.5 Class I events if the whole window were fully reflected in the database by resolution time. But the question resolves using the database state on August 7, 2026 (or August 8-9 only if unavailable), and openFDA’s weekly update cadence plus the observed lag makes the August 5, 2026 report-date week less likely to be fully present two days later. So I discounted the event expectation modestly, to something like 4.0-4.3 Class I events actually visible by the resolution query. That lag adjustment is one of the main reasons I am below the straight 57-day prorating. (open.fda.gov)

Next I translated events into the question’s counting unit, which is closer to distinct identifier-level enforcement rows. FDA’s 2025 annual report says 321 recall events totaled 755 recalled products; FDA’s 2023 annual report says 264 recall events totaled 1,178 violative drug products. Separately, openFDA’s statistics page reports 17,583 total drug enforcement records in the dataset. Because the resolution explicitly counts distinct recall-identifier rows rather than just one count per recall event, the final answer should be materially higher than the raw event count. I therefore treated a rough conversion of about 2-3 counted rows per Class I event as the most defensible range, with a midpoint near 2.5. Multiplying ~4.1 visible Class I events by ~2.5 rows/event gives an expectation near 10; allowing for occasional multi-SKU or multi-lot cluster recalls pushes my mean slightly higher, to about 10.8. This event-to-row conversion is an inference from FDA totals, not a directly published FDA parameter. (fda.gov)

I also checked whether 2026 seems unusually quiet. FDA’s current drug-recall pages show several 2026 drug recall announcements already, including Amneal’s March 24, 2026 magnesium sulfate / tranexamic-acid misfill announcement, Haleon’s June 4, 2026 Gas-X recall announcement, and BD’s June 8, 2026 ChloraPrep announcement. FDA also notes that not all recalls are announced on FDA.gov or in the news media, while all recalls are posted in the Enforcement Report. So recent public announcements tell me the system is active, but they are not a one-for-one proxy for the openFDA enforcement-row count used for resolution. (fda.gov)

Putting that together, my forecast is centered in the high single digits to low teens, with the most likely outcomes around 8-12. I used an overdispersed count model rather than a simple Poisson because one sterility, contamination, or mislabeling cluster can create several identifier-level rows at once. I assigned a modest right tail into the mid-to-high teens for that reason, but very little mass above the mid-20s. In words: my best point forecast is about 10 or 11, with mean ~10.8, median around 10, and most of the probability concentrated from roughly 5 to 17. (open.fda.gov)

Resolution is based on the openFDA drug enforcement endpoint. In this dataset, product_type for drug queries is always Drugs, report_date is the date the FDA issued the enforcement report, and openFDA says the data are updated weekly. FDA also says Enforcement Report data are available through the weekly publication, search functions, and an API. As of Wednesday, June 10, 2026, the openFDA drug-enforcement overview says coverage currently runs only through 2026-05-27, so none of the target-window dates are yet in the public data; this is effectively a full forward forecast rather than a nowcast. (open.fda.gov)

The target window from June 10, 2026 through August 5, 2026 is 57 days long. Because FDA describes Enforcement Reports as weekly and openFDA says this endpoint updates weekly, I treat the window as roughly nine weekly report dates: June 10, June 17, June 24, July 1, July 8, July 15, July 22, July 29, and August 5. That exact Wednesday cadence is an inference from the weekly-publication/update language plus the currently displayed coverage date of Wednesday, 2026-05-27. (fda.gov)

For a long-run base rate, the openFDA interactive chart currently shows 17,661 total drug enforcement reports in the database, and FDA’s iRES search page says the oldest classified date available there is 06/08/2012. A third-party interface built on the same openFDA endpoint reports approximately 1,718 Class I drug reports out of those 17,000-plus total, or about 9.7% of drug enforcement rows. Using that share as a rough baseline implies about 123 Class I rows per year since mid-2012 and about 19.2 Class I rows in a 57-day window. I do not treat the 1,718 figure as authoritative resolution data; I use it only as a rough share estimate and therefore keep the final distribution wider than a pure Poisson fit. (d29vrquxw1xka0.cloudfront.net)

I then adjusted downward for recent conditions. A 2024 analysis using FDA recall data recorded 15,710 drug-recall observations from June 2012 through August 2023. Compared with the current 17,661 total, that suggests the post-August-2023 all-class pace has been materially lower than the full 2012-2026 average. FDA’s own FY2021 pharmaceutical-quality report also says both total recalls and Class I recalls rose for a second year because of event-driven hand-sanitizer methanol and benzene contamination episodes, which argues against extrapolating the pandemic-era spike straight into summer 2026. That pushes me below the pure long-run 19-row estimate. (sciencedirect.com)

My final forecast blends three scenarios with overdispersion: a quieter recent-regime scenario centered near 11, a middle scenario near 15, and a reversion-to-long-run scenario near 19. I weight them 25%, 50%, and 25%, respectively, and use negative-binomial dispersion to allow clustering from a single contamination, sterility, or labeling problem that creates many distinct recall identifiers in one weekly publication cycle. This yields a mean essentially equal to 15, with most probability mass in the low-teens through high-teens and a smaller but meaningful tail into the 20s. My practical point forecast is 15 Class I drug recall enforcement reports in the window. (sciencedirect.com)

My forecast is for the number of Class I drug enforcement-report rows (distinct recall identifiers, per the question’s counting rule) whose report_date falls from June 10, 2026 through August 5, 2026 inclusive. The openFDA drug enforcement endpoint pulls from FDA’s Recall Enterprise System, covers 2004-present, and is updated weekly; the field reference says report_date is the date FDA issued the enforcement report, and for this endpoint product_type is always Drugs. The iRES search page also shows enforcement reports are organized around classified dates and weekly enforcement reports. (open.fda.gov)

For base rates, the most useful hard class-mix datapoint I found was FDA’s FY2023 Office of Compliance annual report. It says CDER classified 264 drug recall events totaling 1,178 violative drug products in FY2023, and the class split was 28 Class I, 172 Class II, and 64 Class III events. That implies a Class I share of about 10.6% of recall events. FDA’s general definition of Class I is a recall with a reasonable probability of serious adverse health consequences or death. (fda.gov)

Recent overall drug-recall volume has varied a lot. FDA’s FY2022 report says 343 drug recall events totaling more than 1,500 recalled products, while FDA’s 2025 annual report says 321 drug recall events totaling 755 recalled products. The same 2025 report says that between 2012 and 2025 more than 17,000 drug products were recalled. So the total row count in any ~8 week window can move materially even if the underlying process is still “business as usual.” (fda.gov)

The target window is 57 days long and, because June 10, 2026 and August 5, 2026 are both Wednesdays, it covers 9 weekly report dates (calendar inference). I used two simple benchmarks. First, if I apply the FY2023 Class I share to the fresher 2025 product-volume environment, I get about 12.50 expected Class I rows in a 57-day window. Second, if I instead combine that same Class I share with FY2023’s much higher products-per-event level, I get about 23.72 rows. Those are not exact truths; they are bounding anchors built from the observed FDA volumes. (fda.gov)

I therefore center the forecast between those anchors, but I lean more toward the lower/fresher side because 2025 is the most recent full-year volume signal I found. I still keep a meaningful upper tail because Class I drug recalls can cluster: a single contamination, sterility, or mix-up episode can create multiple report rows. That logic leads me to a mean just under 16, with the highest single-count probabilities in the mid-teens. My practical 80% interval is roughly 9 to 23, with a thinner but real tail into the upper 20s and low 30s. (fda.gov)

I anchored on FDA’s own definitions and reporting structure. FDA says a Class I drug recall is the most serious category, with a reasonable probability of serious adverse health consequences or death. For the openFDA drug enforcement endpoint, the source is the FDA Recall Enterprise System, the data are updated weekly, and the report_date field is the date FDA issued the enforcement report for the recall. FDA also says recalls monitored by FDA are included in the weekly Enforcement Report once classified. That means this question is fundamentally about the flow of Class I drug records into weekly enforcement reports, not just press releases. (fda.gov)

For base rates, the best official evidence I found was from CDER Office of Compliance annual reporting and the recent FDA drug-recall podcast. Those sources show Class I drug recall event counts in the same broad annual range but with meaningful variation: FY2023 had 28 Class I recall events; 2025 had 29; 2021 had 57 Class I events totaling 138 drug products; 2020 had 48 Class I events totaling 110 drug products; and 2019 had 36 Class I events totaling 513 drugs. In the 2026 podcast, FDA said the total number of recall events has remained fairly steady over the past few years, while the number of affected drugs within each event can fluctuate materially year to year. (fda.gov)

The resolution count is closer to product-level records than to recall events, so I translated recent event counts into likely record counts. As an inference from the official 2020 and 2021 reports, Class I recalls averaged about 2.3 to 2.4 counted drug products per Class I event in those years: 110 divided by 48 in 2020 and 138 divided by 57 in 2021. Applying that recent product-per-event ratio to the newer 28-29 event years implies something like the mid-60s Class I drug records in a full year. Scaling that to the June 10, 2026 through August 5, 2026 window, which is 57 days, gives a rough baseline around 10 to 11 records before timing adjustments. I did not make a strong summer-seasonality adjustment because the FDA material points much more toward manufacturing-quality and contamination drivers than toward a clearly seasonal recall cycle. (fda.gov)

I then widened the distribution because the product count per event can spike. The 2019 report is the clearest warning sign: only 36 Class I events, but 513 drugs. That is exactly the pattern that creates fat right tails for a product-record forecast. The FY2023 report said the top reasons for recall were CGMP deviations, lack of assurance of sterility, and failed impurities or degradation specifications, and the 2026 FDA podcast likewise emphasized contamination-related drivers and said the number of affected drugs per recall can swing year to year. So I do not think a thin Poisson around 10 is appropriate; there needs to be meaningful probability on the high teens and 20s. (fda.gov)

I also made a small downward timing adjustment for possible API lag. openFDA says the drug enforcement dataset is updated weekly, and the current openFDA overview snippet showed coverage through May 27, 2026 in early June 2026 rather than all the way through the current date. That suggests a modest lag between weekly enforcement publication and appearance in the API. Because the question resolves by querying openFDA on August 7, 2026, I allow some chance that the August 5, 2026 weekly report is not fully reflected by the resolution query even though it is inside the nominal date window. This trims the mean a bit rather than changing the whole story. (open.fda.gov)

Putting those pieces together, my forecast is centered near 10 records, with most probability mass in the high single digits through the low teens, but with a meaningful right tail if a broader multi-product Class I recall occurs during the window. The code implements that judgment as a compound-Poisson model over Class I recall events, with a mostly small product-per-event distribution plus a small large-event component, and a modest mixture over quieter versus busier event-rate scenarios. (fda.gov)

How many Class I drug recall enforcement reports will the FDA publish with a report date between June 10 and August 5, 2026?

• My most likely prediction for Class I drug recall enforcement reports is 2.51, with a 50% chance of falling between 0.51 and 14.57.
• Historical data from the openFDA database suggests a low baseline for Class I reports, which typically make up a small percentage of total drug enforcement actions.
• The counting unit (distinct recall identifiers) creates significant ‘cluster’ risk; a single sterile contamination event involving multiple product strengths can rapidly inflate the count.
• Recent 12-year highs in recalled units in early 2026 suggest a high-pressure regulatory environment, but most recent major actions have been classified as Class II.
• Significant warning letters issued to Medline and Endo USA in May 2026 for bacterial contamination could trigger Class I reports if classified within the summer window.
• Administrative lags in the FDA’s classification process often push reporting dates several weeks or months after the initial recall initiation.

Key figures

Historical context

• As of June 3, 2026, the openFDA drug enforcement database contained 17,683 total records since 2004, averaging ~804 per year across all classes.
• Class I recalls typically account for a small fraction (estimated 5-15%) of total drug enforcement reports.
• In Q1 2026, the pharmaceutical sector saw a 12-year high in the number of units impacted (218.8 million units) but a decrease in the number of distinct recall events.
• In 2015, mislabeling was a primary driver of drug recalls, accounting for approximately 42% of events.
• Significant manufacturing failures in late 2011/early 2012 at third-party sites (e.g., Novartis Lincoln) previously led to major analgesic supply constraints and subsequent regulatory actions.

Tailwinds

• Multi-identifier counting: A single major recall of a drug with multiple strengths or lot numbers will generate numerous reports in the database.
• Severe contamination issues: Recent warning letters regarding Bacillus cereus and aseptic process violations are prime candidates for high-severity Class I classifications.
• Heightened regulatory scrutiny: Under the current administration, the FDA has signaled a focus on transparency and ‘regulatory shaming’ through enforcement reports.

Headwinds

• Administrative and classification lags: The FDA often takes weeks or months to formally classify a recall as Class I and post it to the Enforcement Report database.
• Shift to Class II: Many recent significant recalls (e.g., amlodipine/olmesartan and cough drops in mid-2026) were classified as Class II rather than the more severe Class I.
• Declining event frequency: Despite high unit volumes, the total number of individual recall events decreased by 10.5% in the most recent quarter (Q1 2026).

Detailed reasoning

My prediction is based on a synthesis of historical base rates, the specific counting methodology of the openFDA database, and recent regulatory indicators. Historically, the openFDA drug enforcement database has accumulated approximately 17,683 records over 22 years (2004–2026), which averages to roughly 800 reports per year across all classes (I, II, and III). Class I recalls, the most severe category, typically represent a small minority of these actions. Scaling this annual baseline to a 57-day (approximately 8-week) window suggests a neutral expectation of only a few Class I reports.

I have weighted the forecast toward the lower end of the provided scale for several reasons. First, the openFDA database reflects records only after they have been formally classified following a Health Hazard Assessment. This administrative lag means that even if a recall is initiated in June, its formal enforcement report may not appear in the database until after the August 5 cut-off. Second, recent news reports from early 2026 show that while the volume of units recalled is at a 12-year high, the actual number of recall events has decreased by 10.5% quarter-over-quarter. This suggests that the FDA is dealing with larger batches rather than a higher frequency of enforcement actions.

However, a significant source of uncertainty—and the reason for the right-skewed 50% HDI (0.51 to 14.57)—is the ‘recall identifier’ counting unit. Under the resolution criteria, if a single recall event involves multiple strengths or package sizes, each receives a distinct identifier and counts as one report. Recent warning letters issued in April and May 2026 to Par Health USA, Endo USA, and Medline Industries regarding sterile manufacturing and bacterial contamination (Bacillus cereus) provide ‘tail risk.’ If any of these lead to a Class I classification for a diverse product line within the window, the count could quickly jump into the double digits. Given that most recent 2026 recalls have been classified as Class II, I have placed the most likely value at 2.51, representing a typical, relatively quiet summer reporting period, while maintaining a tail that accounts for potential multi-identifier clusters.

Key uncertainties

• Classification timing: The exact date the FDA assigns a ‘Class I’ status and publishes the report is discretionary and can vary significantly.
• Reporting lag: The openFDA API is updated weekly; records with a report date near August 5 may not be visible in the August 7 resolution query.
• Identification of ‘distinct units’: If the FDA groups multiple lots under one identifier, the count will be low; if they use distinct identifiers for every variant, the count will spike.

Conclusion

• The FDA’s Class I drug recall enforcement reports for the mid-summer 2026 window are most likely to follow a low baseline of roughly 2.5 reports, with a significant probability of remaining under 15 reports.
• While high unit volumes in Q1 2026 and recent warning letters to manufacturers like Medline and Endo suggest systemic quality issues, these factors are more likely to manifest as Class II recalls or appear in the database outside of the strict 8-week reporting window.
• Decision-makers should monitor the openFDA API for ‘bursts’ of reports, as the counting methodology (per recall identifier) means a single contamination event can rapidly inflate the count from single digits to dozens within a single weekly update.

Question: how many FDA openFDA “Class I” drug enforcement records will have report_date in 2026-06-10 to 2026-08-05 (inclusive) when the openFDA drug enforcement API is queried on 2026-08-07. All teams agree the correct resolver is a direct openFDA count of report_date in that 57‑day window and that the 2012–2025 same-window history is the best anchor (14 years: mean ≈ 15.9, median ≈ 10.5, min 3, max 42). Forecasters uniformly emphasize strong lumpiness — single multi-product contamination or sterility events can create many rows — and found no clear upward trend, so an overdispersed count family (negative binomial / Poisson‑lognormal / rounded lognormal) is appropriate. Current pre-window indicators (mirrors like NDCList and recent FDA announcements) look relatively sparse, so most teams center the median near 11–12, but they keep substantial right‑tail mass: p90 in the low–mid 30s and p95 in the low–mid 40s. Key monitoring advice agreed upon is weekly openFDA queries of the exact resolution search plus scrutiny of “Not Yet Classified” or severe contamination/sterility announcements that could be reclassified into Class I before Aug. 7. Minor differences between models are only in exact tail quantiles and an exceedingly small nonzero probability reserved by some teams for an extreme >200 multi‑row cluster.

Forecast and Reasoning

Forecast: Probability distribution:

• 10.00% chance of value below 4.905886
• 20.00% chance of value below 6.058893
• 40.00% chance of value below 8.070076
• 60.00% chance of value below 11.161429
• 80.00% chance of value below 16.63109
• 90.00% chance of value below 24.476843

Forecast Reasoning

This resolves to the count of openFDA drug/enforcement records with classification “Class I” whose report_date falls in 2026-06-10 through 2026-08-05 (inclusive), as of the database snapshot queried on 2026-08-07.

I weight most heavily the analysts who directly queried openFDA for (a) the same date window in prior years and/or (b) 2026 year-to-date pace. Those API-based baselines suggest a typical summer-window level roughly in the high single digits to low teens, with meaningful inter-year variability (e.g., one cited set of same-window counts spanning roughly 8–21 across 2022–2025) and indications of a lower 2026 pace so far. The other analysts’ much higher medians (16–25+) rely more on secondary “annual recall” statistics or broad recall totals and appear to overstate Class I drug enforcement-report volume relative to the API-derived window counts.

Synthesis: I set a median slightly below the historical-window median (to reflect the hinted 2026 slowdown), but keep a fat upper tail because occasional contamination/sterility events can generate many distinct recall identifiers in a short period. I keep essentially all mass within the in-range bounds; an extreme >200 outcome in this ~8-week window seems possible but far below 1% given the historical window counts cited.

An amateur forecast is likely to (1) extrapolate from all drug recalls rather than the filtered Class I subset in openFDA, (2) ignore that the unit is distinct enforcement-report records (recall identifiers) with a specific report_date field, and/or (3) anchor on one recent year without accounting for both the apparent 2026 pace shift and the possibility of rare multi-product spikes. This forecast instead combines multiple years of same-window openFDA counts with an explicit downshift for 2026-to-date uncertainty and preserves a realistic right tail for clustered events.

Forecast rationale (numeric):

— Iteration 1 — The forecasts converge on a few core ideas:

• Base-rate driven expectation: All three use historical FDA Class I drug recall frequencies as the starting point, then scale that rate over the roughly 8–9 weekly reporting dates in the June 10 to August 5 window.
• Publication timing matters: One rationale explicitly notes that the August 5 report date may not be fully reflected by the query date, so the effective window could be slightly shorter.
• Strong overdispersion / clustering: A major shared point is that recall reports are not well-modeled by a tight Poisson-like process. A single contamination, sterility, or manufacturing issue can produce many recall identifiers, so the count can spike sharply even if the underlying number of incidents is small.
• Right-skewed uncertainty: Each model treats the distribution as heavily right-skewed, with a modest central estimate but a long tail for rare cluster events. The lower tail allows for a quiet period or reporting lag, while the upper tail remains wide to accommodate unusually large recall waves.

Areas of consensus

• The most likely outcome is not near zero, but also not necessarily extremely large.
• The distribution should be wide, because one event can create many reports.
• A moderate count is the central expectation over this time span.

Main disagreement

• The main divergence is in the central tendency:
  • Two forecasts center in the low-to-mid teens.
  • One places the center substantially higher, around the mid-20s to 30 range, citing a rising recent trend and higher historical window totals.

Overall synthesis

Taken together, the reasoning suggests that the expected number of Class I drug recall enforcement reports over this period is best understood as a multi-week, base-rate-driven count with substantial upside risk from clustered events. The collective view is that the most plausible outcome is somewhere in the teens to low 20s, but with a very wide distribution because a single major recall episode could materially increase the total.

— Iteration 2 — The forecasts largely converge on a mid-teens expectation for the number of FDA Class I drug recall enforcement reports in the June 10–August 5, 2026 window, with a typical center around 14–18 reports. The main reasoning combines historical frequency, recent trends, and how the FDA records recall reports.

Key reasoning patterns

• Historical rate-based extrapolation: The window covers roughly 57 days, so several models convert annual or weekly historical averages into an expected count for that span.
• Recent-year adjustment: While older long-run averages imply something closer to ~20 reports, recent years appear somewhat lower, pulling the estimate down into the low-to-mid teens.
• Record-count methodology matters: The forecasts account for the fact that the FDA may publish separate enforcement report rows for distinct recall identifiers, which can increase counts when a single event generates multiple reports.
• Classification timing effects: One model notes a likely downward bias because recalls posted during the period may not be officially classified as Class I until after the cutoff date used for counting.

Areas of consensus

• The most likely outcome is not a very low count or a major surge; rather, it is a moderate number of reports near the historical middle.
• All models treat the distribution as highly right-skewed, meaning the most probable range is moderate, but rare large events can push the count much higher.
• There is broad agreement that outlier events are the main source of uncertainty, not the baseline monthly pace.

Main sources of uncertainty

• Large recall clusters: A single contamination or batch issue can create many distinct Class I report rows.
• Historical anomalies: A major spike year like 2019 shows that counts can be far above normal.
• Seasonal quiet periods: A relatively calm summer and classification delays could keep totals toward the lower end.

Overall synthesis

The collective reasoning points to a baseline estimate in the mid-teens, with wide asymmetric uncertainty: modest downside if the period is quiet or classifications lag, and substantial upside if a large recall episode generates many distinct FDA reports.

— Iteration 3 — Across the forecasts, the reasoning is broadly consistent:

Core basis for the estimate

• All models anchor on recent historical Class I drug recall rates, especially the 2020–2024 pattern, which implies a typical count in the mid-teens to low twenties over the relevant roughly 57-day window.
• This historical baseline is treated as the best starting point, with the expectation that the number of FDA enforcement reports in the period will usually be moderate rather than extreme.

Main adjustment factors

• Data lag / reporting delay: A major shared adjustment is the possibility that the FDA/openFDA reporting pipeline lags behind real-world events. One model explicitly reduces the estimate because the query date is only a couple of days after the window closes, making the last week of reports potentially incomplete.
• Clustering of recalls: The forecasts assume the distribution is right-skewed, because a single broad recall can generate multiple enforcement report rows. This means the count can jump well above the typical range in rare cases.
• Outlier history: The 2019 spike is used as evidence that very high outcomes are possible, even if they are unlikely. This supports a heavy upper tail rather than a narrow distribution.

Consensus view

• The central estimate across models is clustered around the mid-teens to about 20 reports.
• There is agreement that the most likely outcome is not zero or a very large spike, but a moderate count close to recent norms.

Areas of disagreement

• The main differences are in:
  • How much to discount for reporting lag: one model pulls the median down to around 14, while others stay closer to 17–20.
  • How wide the tail should be: some forecasts allow for more extreme upper-end outcomes than others, reflecting uncertainty about rare clustered recalls.

Overall synthesis

The forecasts collectively suggest that the expected number of Class I drug recall enforcement reports for this period is driven by recent historical averages, moderated downward somewhat by reporting lag, and broadened by the possibility of clustered recall events. The result is a mid-teen to low-20s central expectation with a substantial right tail for rare but plausible spikes.

SUMMARY

Question: How many Class I drug recall enforcement reports will the FDA publish with a report date between June 10 and August 5, 2026? Final Prediction: Probability distribution:

• 10.00% chance of value below 4.99
• 20.00% chance of value below 7.49
• 40.00% chance of value below 11.49
• 60.00% chance of value below 14.99
• 80.00% chance of value below 24.99
• 90.00% chance of value below 36.99

Total Cost: extra_metadata_in_explanation is disabled Time Spent: extra_metadata_in_explanation is disabled LLMs: extra_metadata_in_explanation is disabled Bot Name: extra_metadata_in_explanation is disabled

Report 1 Summary

Forecasts

Forecaster 1: Probability distribution:

• 10.00% chance of value below 5.49
• 20.00% chance of value below 8.49
• 40.00% chance of value below 12.49
• 60.00% chance of value below 16.49
• 80.00% chance of value below 26.49
• 90.00% chance of value below 38.49

Forecaster 2: Probability distribution:

• 10.00% chance of value below 4.49
• 20.00% chance of value below 6.49
• 40.00% chance of value below 10.49
• 60.00% chance of value below 13.49
• 80.00% chance of value below 23.49
• 90.00% chance of value below 35.49

Research Summary

The research identified several recent Class I drug/device recall reports in late May–early June 2026 (examples cited include recalls involving Arrow International dialysis catheter kits, Omnicell syringe labels, and JCB Flavors seasoning products) and used the openFDA enforcement dataset to estimate historical baseline rates. openFDA’s drug enforcement data (covering 2004 through early June 2026) shows about 1,718 Class I drug recalls total; dividing that total across ~22 years yields an average near 78 Class I recalls per year (≈6–7 per month). Using that baseline, the research computes a simple extrapolation for the 57-day window (June 10–August 5, 2026, ≈1.9 months) of roughly 12 Class I reports, while noting substantial uncertainty.

The research also documents key procedural and contextual points: the question specifically hinges on FDA “report_date” (the date FDA publishes the enforcement report), which can lag the company recall initiation; openFDA data are updated weekly and distinguish multiple recall dates (initiation, classification, report_date, termination); Q1 2026 showed an elevated pharmaceutical recall volume (a 12-year high in recalled units) though the number of events changed differently; and no prediction markets on this specific question were found on Metaculus, Manifold, or Polymarket during searches. Data sources consulted include openFDA and FDA recall pages and major prediction-market sites.

Sources used:

• https://open.fda.gov/apis/drug/enforcement/
• https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
• https://www.metaculus.com
• https://manifold.markets
• https://polymarket.com

RESEARCH

Report 1 Research

I’ll help you gather comprehensive information to assist with this forecast. Let me conduct several searches to find relevant news, historical data, base rates, and any prediction markets.

Forecast — Post 450

Modal: 0-25 (78.0%) • partial_shift • 7m19s

Interpretation

Reading: strict

The resolution criteria are highly specific: they name a single authoritative source (openFDA Drug Enforcement API exclusively), a precise date window (June 10–August 5, 2026 inclusive), a specific classification (Class I), a specific product type (Drugs), a specific query date (August 7, 2026), and explicit counting rules (each distinct recall identifier counts once). There is no room for charitable interpretation or inclusion of tangentially relevant recalls — the criteria explicitly exclude everything outside the named parameters.

Time bounds

• observation_window: openFDA Drug Enforcement database state on 2026-08-07 (with fallback to 2026-08-08 or 2026-08-09), counting records with report_date from 2026-06-10 to 2026-08-05 inclusive
• resolution_date: 2026-08-07

Edge cases identified

1. Records that appear in FDA press announcements or other FDA data sources but have not been assigned a database record in openFDA by the resolution query date are excluded — the openFDA API is the sole authoritative source.
2. If a single physical recall produces multiple rows with distinct recall identifiers, each qualifying row counts as one unit; duplicate recall identifiers would count only once.
3. Records added or modified after the resolution query is executed (even if their report_date falls in the window) are not counted.
4. The openFDA API may index records with a slight lag from actual enforcement report publication; recalls processed after August 5 but before the query could appear or not appear depending on exact database update timing.
5. The question window starts June 10 (today), so any Class I drug records already in the database with report_date = 2026-06-10 would count toward the floor.
6. If the openFDA API returns paginated results, the resolver uses the total count metadata ($.meta.results.total), not a manual page count.
7. Edge case on ‘product_type’: the criteria specify ‘drug’ product category; the openFDA field product_type should be ‘Drugs’ — if there are ambiguous categories (e.g., drug-device combos), their inclusion/exclusion could affect the count.

Research (3/3 variants, shared evidence pool)

Total evidence registered (shared pool): ?

Research Brief

Evidence confidence: medium

Scenario 1: Mid-range accumulation: 14–22 records [high evidence]

Conditions favoring

Historical weekly rates of 1.65–2.6 Class I drug records/week continue through the 8-week window without major disruption. FDA enforcement processing continues at recent pace. No unusual regulatory events (mass recalls, contamination events) or significant slowdowns.

Conditions against

FDA workforce reductions (21% staff loss) may suppress enforcement processing below historical rates; alternatively, a contamination/quality event could spike counts above this range.

Scenario 2: Below-historical: fewer than 14 records [medium evidence]

Conditions favoring

FDA workforce reductions (source 33: ~21% staff loss, 3,500+ positions cut in April 2025) reduce enforcement processing capacity; overall recall frequency already declining (source 8: Q4 2025→Q1 2026 drop); recall event counts in FY2024 (source 13) lower than prior years suggesting structural reduction in processed recalls.

Conditions against

Drug warning letters up 59% in FY2025 and inspections at record highs in FY2024 (source 14) suggest a pipeline of enforcement actions still feeding through; historical Class I rates have been durable across multiple measurement methodologies.

Scenario 3: Above-historical: more than 22 records [medium evidence]

Conditions favoring

Drug inspections and warning letters surged in FY2024–2025 (source 14), creating a backlog of enforcement actions that resolve into recalls in 2026. A major contamination event or quality crisis in the window could spike counts. Database row inflation (source 20) — a single recall event generating many rows for each affected NDC/product — could push totals higher than event counts suggest.

Conditions against

No specific evidence of a pending mass recall event; overall FDA activity declining (source 8); workforce reductions constrain throughput; FY2024 product recall counts were at 5-year lows (source 13).

Scenario 4: Very low: fewer than 8 records [low evidence]

Conditions favoring

Severe enforcement slowdown due to DOGE/HHS cuts (source 2, 33); FDA processes recalls but with significant delays pushing report_dates outside the window; the ~86/year (lower bound historical estimate) yields only ~13 per 8 weeks, and if 2026 is below historical norms, could fall to single digits.

Conditions against

Even the lowest credible annual estimate (~46/year from source 3) yields ~7 per 8-week window, making truly minimal counts require historically unprecedented suppression; drug enforcement has continued through all prior workforce disruptions; Class I recalls are high-priority and unlikely to be deprioritized.

Key uncertainties

• Whether 2026 FDA Class I drug recall processing rates are elevated (due to the inspection/warning letter surge in FY2024-2025) or depressed (due to workforce reductions) relative to historical baselines
• Whether the openFDA row count per Class I drug recall event is closer to 1:1 or significantly higher (multiple NDCs per recall event counted as separate rows)
• The exact weekly cadence of report_dates in the window — there are approximately 8 weekly enforcement reports between June 10 and August 5, 2026, but the exact number depends on the weekly publication schedule
• Whether DOGE/HHS workforce reductions materially delayed or suppressed FDA enforcement processing of drug recalls specifically (as opposed to device recalls)
• Whether any major drug quality/contamination event occurs in the June–August 2026 window that would spike counts above historical norms

Forecast variants (3/3)

Variant 0: inside_view (inside_view_v1)

Inside-View Causal Analysis

Causal chain: Historical FDA enforcement processing → weekly openFDA database updates → accumulated Class I drug recall records in 8-week window.

Key mechanism: The FDA publishes enforcement reports weekly. Each week produces some number of Class I drug recall rows in openFDA. The resolution window covers ~8 weekly enforcement report cycles (June 10 to August 5, 2026). The count is the sum of all qualifying rows across those ~8 cycles.

Scenario weighting by evidence strength:

1. Mid-range (14–22 records) — relative_evidence_strength: high: This scenario is supported by multiple independent historical sources: peer-reviewed study (source 7) gives ~2.4/week → ~19 records; RecallCheck (source 17) gives ~1.65/week → ~13 records; Lightfoot Law (source 4) gives ~2.6/week → ~21 records. The convergence of multiple methodologies around 13–21 records is strong. A Poisson model centered at ~2.0–2.4/week over 8 weeks gives mean ~16–19, p5 ~8–10, p95 ~26–30.

2. Below-historical (<14 records) — relative_evidence_strength: medium: FDA workforce reductions (~21% staff loss per source 33), overall recall frequency declining (source 8: Q4 2025→Q1 2026 drop), and FY2024 recalled products at 5-year lows (source 13) all push toward lower counts. But enforcement of Class I (highest hazard) recalls is unlikely to be significantly deprioritized.

3. Above-historical (>22 records) — relative_evidence_strength: medium: Drug inspections surged to 972 in FY2024 and warning letters jumped 59% in FY2025 (source 14), suggesting enforcement pipeline buildup. Additionally, openFDA rows can exceed events due to multi-product recalls (source 20).

4. Very low (<8 records) — relative_evidence_strength: low: Requires historically unprecedented suppression; Class I recalls are prioritized.

Distribution construction:

• The high-evidence mid-range scenario (14–22) covers bin_1 partially and bin_2 primarily (25–50 is too high; the range 14–22 falls in the 0–25 bin range entirely).
• Wait — the bins are: bin_1: 0-25, bin_2: 25-50, bin_3: 50-75…
• So 14–22 records all fall within 0–25 (bin_1). The Poisson p95 is ~26–30, meaning most of the distribution is in bin_1, with a small amount spilling into bin_2.

Re-mapping:

• 0-25 (bin_1): The central estimate (16-19) plus the bulk of Poisson spread falls here. Given the high-evidence scenario centers on ~16-19 with p95 around 26-30, approximately 75-80% of mass should be in bin_1.
• 25-50 (bin_2): Above-historical scenario (medium evidence) and the upper tail of the high-evidence scenario both contribute here. ~10-15% mass.
• below 0 (bin_0): Impossible, essentially 0.
• bin_3+ (50+): Very small tail for extraordinary events.
• below-8 within bin_1: Captured inside bin_1; the low-evidence “very low” scenario shifts some mass toward the lower portion of bin_1 but doesn’t take mass out of bin_1.

Final allocation:

• bin_0: 0.00 (impossible)
• 0-25 (bin_1): 0.80 — the high-evidence mid-range scenario (14-22) sits entirely here; below-historical and very-low scenarios also land here
• 25-50 (bin_2): 0.14 — upper Poisson tail plus above-historical scenario
• 50-75 (bin_3): 0.04 — very small but not zero for contamination/batch events
• bin_4+: minimal residual

Variant 1: outside_view (outside_view_v1)

Reference class: count of Class I drug recall rows in the openFDA Drug Enforcement database over an ~8-week window (the resolution window June 10–Aug 5, 2026). Base-rate evidence: multiple data summaries place the historical weekly rate of Class I drug recall rows between ~1.65/week and ~2.6/week (RecallCheck/tryopendata ~1.65/week; peer-reviewed 2012–2023 ~2.4/week; Lightfoot Law ~2.6/week) which maps to ~13–21 rows over ~8 weeks and a Poisson-style projection centered ≈16–19 records for the window (sources 17, 7, 4, computation). The openFDA enforcement reports publish weekly, so the window covers ≈8 report_date cycles (sources 5, 10).

Adjustment: I place the bulk of probability in the 0–25 bin because the base-rate projection (≈16–19) falls well inside that bin and the Research Brief tagged the mid-range accumulation scenario as the strongest-evidence scenario (relative_evidence_strength = high) citing the same base-rate computations (sources 7, 17, 4). Medium-strength evidence (workforce cuts and recent downward trends) supports a lower-than-historical outcome, and medium-strength evidence (inspection/warning-letter surge and possible multiplicative database rows per event) supports a modest chance of higher totals; a very-low-evidence scenario allows single-digit outcomes if processing is severely suppressed (sources 33, 8, 13, 14, 20). I therefore allocate ~90% probability to 0–25 (bin_1), ~7% to 25–50 (bin_2) to cover plausible above-historical outcomes or database-row inflation, ~2% to 50–75 (bin_3) for rarer large spikes, and distribute a small tail (combined ~1%) across higher bins to allow for extremely unlikely mass-recall or data/aggregation anomalies. Bin_0 (Below 0) is impossible under the strict resolution rules, so probability = 0.

Weighting rationale vs. the brief’s scenarios: the mid-range scenario was tagged high-evidence and therefore dominates the distribution (most mass in bin_1). The two medium-evidence scenarios (below-historical and above-historical) receive the remaining moderate mass (bins 2–3). The low-evidence “very low” scenario receives only a small share reflected in the tiny tail beyond bin_3. All adjustments are conservative relative to the base-rate projection and reflect the brief’s stated uncertainties (workforce reductions, inspection/warning-letter trends, and row-vs-event inflation) cited above (sources 33, 14, 20).

Strict-reading note: I follow the interpretation’s strict reading — only openFDA Drug Enforcement API rows with classification = “Class I”, product_type = “Drugs”, and report_date between 2026-06-10 and 2026-08-05 (as they will appear in the database snapshot on Aug 7, 2026) count; probability mass reflects that exact resolution framing (sources 22–24, resolution rules).

Variant 2: contrarian_v2 (contrarian_v2)

Adversarial reading

The brief’s bulk evidence (historical rates from multiple sources spanning 12–20 years, weekly cadence, Poisson projection) converges on a narrow 13–22 record outcome for the 8-week window. Mid-range accumulation (14–22) is explicitly tagged high-evidence-strength; the two medium-strength scenarios bracket it symmetrically.

Counter-evidence found (or absence)

Substantive counter-evidence exists in the 21% FDA workforce reduction since Sep 2024 plus the already-observed Q4-2025-to-Q1-2026 decline in overall recall frequency and the FY2024 5-year-low product count. These factors are cited as favoring the “below-historical” scenario (medium evidence strength) and could shift the realized count toward the lower half of the 0–25 bin or even single digits.

Distribution implications

Because the high-evidence historical continuity scenario still dominates, the great majority of mass remains inside 0–25 (bin_1). The workforce-reduction counter-evidence justifies a modest right-tail shift into 25–50 (bin_2) relative to a naïve Poisson centered at 18, but not enough to move material probability beyond bin_2. Bins 3+ receive negligible mass given the evidence bounds.

Consolidate

Strategy: logit_mean • Drafts: 3/3

Reviewers (3/3)

anchoring → no_change (low magnitude, medium confidence) anchoring_v1

The draft forecast is well-anchored to the modal expectation, not the optimistic or pessimistic extreme. The p50/mode is centered around 16–19 records (well inside bin_1: 0–25), which reflects the conditional mean of the Poisson projection rather than the front or back end of the plausible range. There is no evidence the forecaster picked the earliest/optimistic candidate or placed peak mass at an extreme — bin_1 holds ~87% of the mass and the central estimate of ~16–19 is drawn from converging historical base rates (~1.65–2.6/week × 8 weeks). The only mild anchoring concern is whether the “above-historical” medium-evidence scenario (which includes database-row inflation per source 20, where a single recall event generates multiple openFDA rows) is adequately represented: if a few large recalls hit during the window each generating 5–10 rows, the realized count could push into 25–50 (bin_2) more frequently than the ~10% assigned. However, this is within normal uncertainty bounds and not a systematic optimistic/pessimistic anchor. The forecast appropriately places the modal expectation near ~17 records and does not treat the worst-case (workforce suppression) or best-case (inspection-pipeline surge) as the central scenario.

Flagged concerns

• Row-vs-event inflation underweighted: Source 20 notes a single recall event affecting multiple NDCs/products generates multiple openFDA rows. If even 2–3 large multi-product recalls land in the window (each generating 5–10 rows), the realized total could reach 30–50. The draft assigns only ~10% to 25–50 (bin_2), which may be slightly low given this structural multiplier — though the historical base rates already implicitly capture row inflation, so this is a modest concern.

ceiling → redistribute (low magnitude, high confidence) ceiling_v1

The most critical structural constraint the draft underweights is the hard weekly cadence ceiling: the brief explicitly states “approximately 8 weekly enforcement report cycles” cover the June 10–August 5 window (57 days ÷ 7 ≈ 8.1 cycles). Each cycle produces a discrete batch of Class I drug recall rows. The historical per-week rate of 1.65–2.6 rows/week × 8 weeks = 13–21 rows, with a Poisson p95 of ~26–30. This means the structural ceiling on the “normal operations” scenario is firmly below 50, and reaching 25–50 (bin_2) already requires the upper tail of the distribution. Yet the draft already allocates ~10.3% to bin_2 and ~2% to bin_3+, which is defensible. The larger concern is that the draft places ~0.1% in Below 0 (bin_0), which is a structurally impossible outcome — counts cannot be negative under any resolution rule. That mass in bin_0 must be redistributed. Additionally, the answer range itself (-0.5 to 200.5) and the “open lower bound” notation in the scaling metadata could tempt a forecaster to assign non-trivial mass below zero, but the resolution criteria make clear this is a count (≥ 0). The structural floor is 0, and the structural ceiling under normal operations is approximately 30–35 (Poisson p99 at λ=19).

Flagged concerns

• impossible_bin_mass: Below 0 (bin_0) receives 0.001 probability. The resolution criteria define the outcome as a count of database records — counts cannot be negative. The brief’s resolution rules (‘integer count of records’) establish a hard floor at 0. This mass is structurally impossible and should be redistributed to bin_1.
• structural_ceiling_underspecified: The brief establishes ~8 weekly cycles × 1.65–2.6 records/week = 13–21 records as the structural central range, with Poisson p99 ≈ 30–35. Bins 3–9 (50+) collectively receive ~2.7% probability. While small, this slightly overstates the probability of outcomes requiring 4–7× the historical weekly rate sustained over 8 consecutive weeks without any documented trigger event. The ‘above-historical’ medium-evidence scenario cites only a pipeline effect and row inflation, neither of which mechanically supports 50+ records.

math → shift_lower (medium magnitude, high confidence) math_v1

The forecast exhibits significant mathematical issues. Most critically, the rationale describes a Poisson projection with mean ~16–19 records and p95 ~26–30, yet the distribution assigns 86.6% to 0–25 (bin_1) and only 10.3% to 25–50 (bin_2). Under a Poisson with mean ~17.5 and p95 ~27, approximately 25–30% should fall above 25, not 10.3%. The rationale explicitly states “approximately 75-80% of mass should be in bin_1,” but 86.6% contradicts both this stated allocation and the implied tail behavior of the Poisson model. Additionally, Below 0 (bin_0) should be 0, not 0.001.

Flagged concerns

• Probability mass inconsistent with stated Poisson tail: Rationale derives Poisson mean ~16–19 with p95 ~26–30 (sources 7, 17, 4, computation), implying ~25–30% mass above 25. Published 25–50 (bin_2) = 10.3%. Inconsistent. Expected bin_2 should be ~0.25–0.30, not 0.103.
• Impossible outcome assigned nonzero probability: Below 0 (bin_0) assigned 0.001 probability. Rationale correctly states this is impossible under resolution rules. Should be exactly 0.000. This alone inflates bin_1 error.
• Total probability: rounding error margin exceeded: Published prediction_map sums to 1.0 exactly (verified), but the allocation across bins deviates substantially from stated rationale targets (76–80% bin_1 vs. published 86.6%). The discrepancy suggests internal contradiction, not rounding.
• Rationale-stated allocation mismatched to published distribution: Inside-view section states ‘Poisson p95 is ~26–30, meaning most of the distribution is in bin_1, with a small amount spilling into bin_2’ and then allocates bin_1=75-80%, bin_2=10-15%. Published distribution is bin_1=86.6%, bin_2=10.3%. The 6–11 percentage-point inflation of bin_1 is inconsistent with the stated rationale’s own math.

Reconcile: partial_shift

Reviews consumed: 3

The draft places ~86.6% in 0-25 (bin_1) with a Poisson projection centered ~16-19. The math reviewer correctly flagged that under a Poisson with mean ~17.5 and p95 ~27, roughly 25-30% of mass should fall above 25, not ~10%. This is a real internal-consistency bug; I integrated it by shifting probability mass from bin_1 down to bin_2 and slightly into bin_3. The ceiling reviewer flagged that Below 0 (bin_0) is structurally impossible — I accepted this and zeroed it out (the draft already had only 0.001 there). The anchoring reviewer found no directional bias and suggested no_change; their concern about row-vs-event inflation reinforces keeping moderate mass in bin_2. I partially shifted toward the math reviewer’s distribution (bin_2 ~0.18) but didn’t go all the way to 0.21 because the workforce-reduction counter-evidence (sources 33, 8, 13) genuinely depresses the right tail, and the Poisson model itself may overstate dispersion for batched weekly reports. Tail bins beyond bin_3 receive minimal mass since the structural ceiling (~8 weekly cycles) makes 50+ records require an unusual mass-recall event.

Rejected critiques

• [math] Suggested bin_2 should be ~0.21–0.30 to match strict Poisson p95 tail

  • Why rejected: Partially accepted (shifted bin_2 up to ~0.18) but did not go fully to 0.21 because (a) workforce-reduction evidence (sources 33, 8, 13) genuinely compresses the upper tail below a pure Poisson expectation, and (b) the weekly batched cadence creates discrete clustering that may have lower variance than a Poisson with the same mean.

• [anchoring] Row-vs-event inflation could push counts into bin_2 more often than 10%

  • Why rejected: Concern integrated indirectly — the shift toward driven by the math reviewer (bin_2) also accommodates this row-inflation concern, so no separate adjustment was needed.

Final Distribution

Evidence Sources (33)

1. MedCon: FDA sees uptick in class I recalls in 2025 as it tackles resourcing issues — In 2025, there were 111 Class I drug recalls and early alerts, and between 2020 and 2025 Class I recalls increased by 232%.
2. In FDA job cuts, experts see threat of far-reaching impact — FDA drug inspection capacity has been reduced due to staffing problems and DOGE/HHS cuts in 2025, with experts warning of far-reaching impacts on FDA’s ability to conduct enforcement activities.
3. The continuing challenge of drug recalls: Insights from a ten-year FDA data analysis — From 2012-2023, approximately 330 drug recalls are initiated each year on average (all classes), with Class I recalls accounting for 14% of events, implying roughly 46 Class I drug recalls per year historically.
4. FDA Drug Recall Statistics [Updated For 2024] - Lightfoot Law — Between 2012 and 2023, 1,636 Class I drug recalls were issued by the FDA (average ~136/year), per Lightfoot Law analysis. On average, 1,284 drugs are recalled every year across all classes.
5. Enforcement Report Information and Definitions - FDA — FDA enforcement reports are published on a weekly cadence — all recalls monitored by FDA are included in the weekly Enforcement Report once classified according to hazard level; report_date in the openFDA database corresponds to the weekly report date.
6. FDA’s Efforts to Recall Faulty Medical Devices Limited by Insufficient Staffing — FDA has insufficient staffing to conduct adequate oversight of recalls (per GAO December 2025 findings), which could create processing delays and backlogs — though this was specifically about medical devices, not drugs.
7. A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023 — From 2012-2023, there were 15,710 total drug recall observations with 1,524 classified as Class I (approximately 127 Class I drug recalls per year over 12 years), suggesting a rate of about 2.4/week or roughly 30 per 8-week period.
8. Product Recalls Drop in Frequency but Surge in Scale, With Units Reaching Four-Year High — Overall U.S. recall event count (all categories) dropped from 877 in Q4 2025 to 785 in Q1 2026, suggesting a declining frequency trend heading into the resolution window.
9. FDA Recall Update: June 2025 — In June 2025, the FDA recalled 3 drug products (all categories), down from 1 drug in May 2025; the total FDA recalls in June 2025 were 23 products (food/drug/device combined). This indicates relatively low drug recall volume in that month.
10. Drug Enforcement Overview - openFDA — The openFDA drug enforcement database is updated weekly and covers 2004-present. Each FDA enforcement report record has a report_date corresponding to the weekly publication of the Enforcement Report.
11. Enforcement Report - Week of June 19, 2024 — In the enforcement report for the week of June 19, 2024, there was at least 1 Class I drug event (Docetaxel Injection from Sagent Pharmaceuticals), and several Class II drug events. The report is published weekly and covers all product types.
12. FDA Drug Recall Statistics [Updated For 2024] - Lightfoot Law — Class I recalls make up approximately 10.4% of all drug recalls per Lightfoot Law analysis of FDA data through 2023; Class II makes up 80% and Class III makes up the remainder.
13. FY2024 Report on the State of Pharmaceutical Quality - FDA — In FY2024 (Oct 2023 - Sep 2024), FDA recorded 260 drug recall events, a 15% increase from FY2023, but the number of recalled products (421) was the LOWEST in five years. FY2023 had 674 recalled products, FY2022 had 912, FY2021 had 787, FY2020 had 691.
14. FDA’s drug quality report notes ‘significant’ uptick in inspections since pandemic - RAPS — FDA drug quality inspections increased significantly: 522 inspections in FY2022, 766 in FY2023, and 972 in FY2024 — drug warning letters also jumped 59% in FY2025. Higher inspection activity is generally associated with more subsequent recalls.
15. MedCon: FDA sees uptick in class I recalls in 2025 - RAPS — The RAPS 2026 article on Class I recall uptick specifically covers MEDICAL DEVICE recalls (not drug recalls); the 111 figure and 232% increase are for medical devices only. Class I drug recalls must be tracked separately from medical devices.
16. FDA Drug Recalls & Enforcement Actions - OpenData (tryopendata.ai) — As of mid-2024, FDA’s total drug enforcement database had approximately 17,500 records total (all classes), with approximately 1,726 Class I drug recalls across the full database history (2004-present). This suggests roughly 127-160 Class I drug records per year in the openFDA database.
17. Drug Recall Classifications — RecallCheck — RecallCheck.net (sourcing openFDA data 2006-2026) shows 17,663 total FDA drug recalls with 1,725 Class I (9.8%), 14,250 Class II (80.7%), and 1,688 Class III (9.6%). This gives an annual average of ~86 Class I drug recalls per year if spread over ~20 years (2006-2026), or ~130-140/year for recent years.
18. MedCon: FDA sees uptick in class I recalls in 2025 as it tackles resourcing issues — CRITICAL CORRECTION: The “111 Class I recalls and early alerts in 2025” figure is specifically for MEDICAL DEVICES, not drugs. This was reported by FDA’s Anne Reid, program director of the Office of Medical Device and Radiological Health Inspectorate (OMDRHI), at the 2026 MedCon conference. The drug recall figures are separate and tracked differently.
19. Multiple sources: FDA drug recall statistics — Based on historical data (2012-2023): 330 drug recalls/year on average across all classes; 14% are Class I = ~46 Class I drug recalls/year = ~0.9 per week. But in more recent years (2020-2025), Class I drug recalls have been trending higher (from the 232% increase figure for devices suggests drug recalls also increased). The 1,726 Class I records in the openFDA database from 2004-present (~20 years) implies ~86/year average, or about 1.65/week.
20. FDA FY2024 Pharmaceutical Quality Report — The openFDA drug enforcement API counts individual rows where each distinct recall identifier (recall_number or product recall number) counts as one record. A single “recall event” affecting multiple products/NDCs would typically appear as multiple rows in the database. This means the count of openFDA rows is generally LARGER than the count of recall events.
21. How to use the endpoint – openFDA Drug Enforcement — The openFDA Drug Enforcement API base endpoint is https://api.fda.gov/drug/enforcement.json, and searches use the syntax search=field:term with an optional limit parameter (max 1000 per call).
22. openFDA Drug Enforcement Fields Reference (PDF) — The correct filterable field for the FDA enforcement report date is report_date (string), defined as “Date that the FDA issued the enforcement report for the product recall.” Date range queries use bracket syntax, e.g., report_date:[20040101+TO+20131231]. This is distinct from recall_initiation_date (date the firm first began notifying the public) and center_classification_date.
23. openFDA Drug Enforcement Fields Reference (PDF) — The product_type field (string) in the openFDA Drug Enforcement API is defined as “The type of product being recalled. For drug queries, this will always be Drugs.” — confirming the exact filter value is Drugs (capital D).
24. openFDA Drug Enforcement Fields Reference (PDF) and Example API Queries — The classification field (string) in the openFDA Drug Enforcement API is defined as “Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard.” The API example query filters it as classification:"Class+III" using exact phrase matching with double quotes.
25. Weekly FDA Roundup: MAHA Takes Shape in Policy, 28 Recalls, and a Wound Care Alert — Week of Jan 17–24, 2026 | Policy Canary — During the week of January 17–24, 2026, FDA had 28 total recalls, with Class I recalls accounting for at least 6 of the enforcement actions (touching supplement companies, a bakery, a chocolate maker, and a grocery retailer) — these are cross-product-type (food, drugs, supplements), not drug-only.
26. Weekly FDA Roundup: Flawed Blood Lead Test, FSVP Enforcement Wave, and 22 Recalls — Week of January 26, 2026 | Policy Canary — During the week of January 24–31, 2026, FDA issued 22 total recalls, of which 3 were Class I, 7 were Class II, and ~12 were allergen/labeling-related; this is across all product categories (food, drugs, devices, supplements) not drug-only.
27. Weekly FDA Roundup: US-EU Pharma Deal Revoked, Blood Glucose Device Death, and 8 Class I Recalls — Week of Feb 14–21, 2026 | Policy Canary — During the week of February 14–21, 2026, FDA issued 28 recalls total, of which 8 were Class I, 19 were Class II, and 1 was Class III; the 8 Class I recalls spanned both food and device categories (e.g. five hummus SKUs and a blood glucose device correction).
28. Weekly FDA Roundup: Compounding Crackdown and Device Safety Alerts — Week of Feb 21–28, 2026 | Policy Canary — During the week of February 21–28, 2026, FDA issued 16 total recalls, including 2 for undeclared prescription drugs in supplement products (likely Class I), plus 10 warning letters and 5 safety alerts.
29. FDA Class I Recalls | Recall Directory — As of April 13, 2026, the recalldirectory.com database (sourced from openFDA) showed 468 total recalls classified as Class I across all product types; examples of 2026 drug Class I recalls include FDA Recall #H-0654-2026 and #H-0655-2026 (undeclared sildenafil, initiated Mar 13, 2026) and #H-0653-2026 (undeclared sildenafil and tadalafil, initiated Mar 13, 2026).
30. US Recall Roundup: Week of April 13–April 17, 2026 | Consumer Recalls USA — During the week of April 13–17, 2026, there were 31 drug and medication recalls (all classes combined) in a single week of 411 total recalls; specific drug Class I recalls cited from that window include undeclared sildenafil/tadalafil products initiated March 11, 2026 (Mohamed Hagar’s Mojo Max Fusion XXX and StuffbyNainax’s MR. 7 SUPER 700000).
31. Characteristics of United States Food and Drug Administration Drug Recalls (Pharmacoepidemiology & Drug Safety) — A February 2026 academic paper in Pharmacoepidemiology & Drug Safety (published Feb 23, 2026) analyzed US FDA drug recall characteristics; Class I recalls (risk of death) comprised 35 events (12.2%) of the studied sample, concentrated among fentanyl (n=10), morphine (n=9), and hydromorphone (n=9).
32. MedCon: FDA sees uptick in class I recalls in 2025 as it tackles resourcing issues | RAPS — FDA saw an uptick in Class I medical device recalls in 2025, with 111 Class I recalls and early alerts for devices in 2025; between 2020 and 2025, Class I (device) recalls increased by 232%. FDA officials stated this upward trend is “concerning” and resource-intensive to track.
33. FDA Workforce Cuts and Medical Device Regulatory Timelines in 2026 | MedDeviceGuide — Since September 2024, FDA has lost approximately 21% of its total workforce (4,400+ people); the Center for Devices and Radiological Health lost ~22% of its workforce, dropping from ~2,260 to ~1,800 reviewers and inspectors; HHS-directed layoffs in April 2025 cut ~3,500 FDA positions (19% of agency).

wooley_rhino • run d5f6db80 • $3.12 • 7m19s

Extracted Percentile Values: {0.1: 0, 1.0: 0, 5.0: 1, 10.0: 2, 15.0: 2, 20.0: 3, 25.0: 3, 30.0: 4, 35.0: 4, 40.0: 5, 45.0: 5, 46.0: 5, 47.0: 6, 48.0: 6, 49.0: 6, 50.0: 6, 51.0: 7, 52.0: 7, 53.0: 7, 54.0: 7, 55.0: 8, 60.0: 8, 65.0: 9, 70.0: 10, 75.0: 12, 80.0: 14, 85.0: 16, 90.0: 19, 95.0: 26, 99.0: 42, 99.9: 65}

Model’s Answer: Looking at this forecasting question, I need to determine how many Class I drug recall enforcement reports the FDA will publish with report dates between June 10 and August 5, 2026 (approximately 57 days, or about 1.9 months).

Key Historical Data Analysis

Annual Class I Drug Recall Rates:

• Harvard Health (2023): ~14,000 drug recalls over 10 years (~4/day), with 6% being Class I in 2022 → ~20 Class I per year
• ScienceDirect (2024): 3,718 recall events 2012-2023 (avg 330/year), with 14% Class I → ~46 Class I per year

Calculating Expected Window Count:

• Lower estimate: 20 × (57/365) ≈ 3.1 Class I reports
• Higher estimate: 46 × (57/365) ≈ 7.2 Class I reports
• Central expectation: ~4-7 Class I drug enforcement reports

Current 2026 Environment Assessment

The research reveals an active recall environment in early-mid 2026:

• Tums and 14 store-brand antacids (May 28 initiation) - metal contamination, potential Class I
• Plastikon Healthcare products (Milk of Magnesia, Acetaminophen) - June 5, 2026
• Gas-X recall for chemical contamination - June 4, 2026
• BD ChloraPrep fungal contamination - June 8, 2026

These clustered OTC/GI product quality issues suggest above-average recall activity entering the forecast window.

Key Assumptions and Risks

Assumption 1: Historical Class I rates (6-14% of total drug recalls) persist in 2026

• Failure probability: ~15% - Could be higher due to current contamination cluster
• Impact: Would shift median upward by 2-4 reports

Assumption 2: Report date lag patterns remain consistent

• Failure probability: ~10% - Administrative delays could shift reports outside window
• Impact: Could reduce or increase count by 2-3 reports

Assumption 3: No major manufacturing crisis creates a super-cluster

• Failure probability: ~5% - A major facility issue could generate 10+ related records
• Impact: Could push count to 25+ range

Low vs. High Outcome Scenarios

Low outcome (0-2 reports): Many announced recalls are classified as Class II rather than Class I; administrative lags push report dates outside the window; current contamination issues resolve without additional serious findings. Likelihood: ~10%

High outcome (20+ reports): Current OTC contamination issues expand to additional products/manufacturers; each multi-product recall generates multiple distinct enforcement records; additional serious quality issues emerge during summer inspections. Likelihood: ~10%

Final Rationale

Step one: I established baseline rates from historical studies suggesting 20-46 Class I drug recalls annually, translating to 3-7 expected in this ~57-day window.

Step two: I assessed current conditions showing multiple active contamination issues in OTC products, suggesting slightly above-average activity.

Step three: I applied appropriate right-skew to the distribution because Class I recall counts can cluster when manufacturing issues affect multiple products from a single source.

Step four: I widened confidence intervals significantly given uncertainty about exact historical rates for this specific metric and window, and the inherent variability in recall timing.

Step five: I set extreme tails conservatively - while 0 is possible in a low-activity period, counts above 40-60 would be extraordinarily unusual absent major systemic failures.

Percentile .1: 0 Percentile 1: 0 Percentile 5: 1 Percentile 10: 2 Percentile 15: 2 Percentile 20: 3 Percentile 25: 3 Percentile 30: 4 Percentile 35: 4 Percentile 40: 5 Percentile 45: 5 Percentile 46: 5 Percentile 47: 6 Percentile 48: 6 Percentile 49: 6 Percentile 50: 6 Percentile 51: 7 Percentile 52: 7 Percentile 53: 7 Percentile 54: 7 Percentile 55: 8 Percentile 60: 8 Percentile 65: 9 Percentile 70: 10 Percentile 75: 12 Percentile 80: 14 Percentile 85: 16 Percentile 90: 19 Percentile 95: 26 Percentile 99: 42 Percentile 99.9: 65

Regulatory publication and classification operate on a slow, programmatic cadence with weekly ingestion windows and discrete enforcement-report records.

Per-product recordization and recall-number rules create a structural floor and allow single incidents to produce multiple database rows.

Year-to-date counts and the recent summers have trended below the multi-year post-2012 average, pulling the central expectation downward.

The historical series is punctuated by clusters tied to multi-SKU manufacturing or contamination episodes, producing a persistent right tail.

A late-week upload, backlog clearance, or a large multi-product recall would shift the count sharply upward within days.

Continued quiet manufacturing surveillance and no emergent contamination events would keep the window near recent low-season levels.

The count is sensitive to public enforcement database update timing and to the August 5 report date falling inside a short post-window update interval.

Limited post-2012 sample size and the lumpiness of multi-row recall events leave substantial residual uncertainty around any single-window expectation.

Final forecast (median): 9.002 Class I drug recall enforcement reports (FDA report_date between June 10 and Aug 5, 2026).

• Summer “baseline” from past years: In comparable mid-June to early-August periods, totals often land around the single digits to low teens, though some years spike.
• 2026 looks unusually slow so far: By June 9, 2026, the published pace is about half of the comparable pace from 2025—pushing the expectation downward.
• Timing and publication lag: The FDA/OpenFDA data updates on a weekly rhythm, so early-in-window reporting can look quiet even if some items appear later.
• Big recall events drive upside risk: Counts can jump if there’s one major batch/contamination-type recall, because that can generate many separate enforcement records in a short span.
• Overall shape is right-skewed: Most outcomes cluster near the center, but there’s a non-trivial chance of ending up notably higher than the median due to bursty recall events.